⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Official Title: A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Study ID: NCT01392443

Interventions

Ruxolitinib

Study Description

Brief Summary: The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the effects of INC424 on patient reported outcomes and the duration of response as assessed by reduction in spleen volume was also assessed.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Novartis Investigative Site, Beijing, Beijing, China

Novartis Investigative Site, Guangzhou, Guangdong, China

Novartis Investigative Site, Wuhan, Hubei, China

Novartis Investigative Site, Nanjing, Jiangsu, China

Novartis Investigative Site, Suzhou, Jiangsu, China

Novartis Investigative Site, Chengdu, Sichuan, China

Novartis Investigative Site, Tianjin, Tianjin, China

Novartis Investigative Site, Hangzhou, Zhejiang, China

Novartis Investigative Site, Jinan, , China

Novartis Investigative Site, Shanghai, , China

Novartis Investigative Site, Nagoya, Aichi, Japan

Novartis Investigative Site, Fukuoka city, Fukuoka, Japan

Novartis Investigative Site, Maebashi city, Gunma, Japan

Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan

Novartis Investigative Site, Tsu-city, Mie, Japan

Novartis Investigative Site, Suita city, Osaka, Japan

Novartis Investigative Site, Bunkyo ku, Tokyo, Japan

Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

Novartis Investigative Site, Seoul, Korea, Korea, Republic of

Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of

Novartis Investigative Site, Seoul, , Korea, Republic of

Novartis Investigative Site, Seoul, , Korea, Republic of

Novartis Investigative Site, Kaohsiung, , Taiwan

Novartis Investigative Site, Taipei, , Taiwan

Novartis Investigative Site, Taoyuan, , Taiwan

Contact Details

Name: Novartis Pharmaceuticals

Affiliation: Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: